GM says slumping Drew Stubbs won't be demoted

2 Comments

Drew Stubbs went 0-for-5 with three strikeouts yesterday to drop his batting average to .174, but general manager Walt Jocketty said today that the 25-year-old center fielder is in no danger of being sent back to the minors:

He needs to works it out on the major league level. You don’t want him to lose confidence. He does so many other things so well. He needs to be a more selective and patient at the plate.

I agree with Jocketty on all fronts. Stubbs isn’t a great prospect, but because the Reds are unlikely to be much better than .500 this season finding out how he and other young players fit into the team’s long-term plans is key. He’s also 25 already, so another stint at Triple-A doesn’t figure to do much good given that he played 126 games there during the previous two seasons.
Jocketty is also right that Stubbs’ approach at the plate likely needs to change for him to have long-term success. He has 79 strikeouts in 301 plate appearances as a big leaguer after whiffing 141 times per 600 plate appearances in the minors. Obviously many sluggers can get away with that many strikeouts, but Stubbs has hit just 38 homers in 1,860 pro at-bats and whatever value he ultimately has will come primarily from defense, speed, and (hopefully) getting on base.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.